Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1955 1
1958 1
1962 1
1963 1
1964 1
1965 1
1973 2
1974 1
1975 1
1977 2
1978 3
1979 4
1980 3
1981 3
1982 5
1983 7
1984 4
1985 4
1986 6
1987 13
1988 13
1989 14
1990 12
1991 15
1992 19
1993 25
1994 24
1995 26
1996 30
1997 34
1998 29
1999 53
2000 42
2001 48
2002 61
2003 80
2004 111
2005 128
2006 131
2007 136
2008 183
2009 176
2010 240
2011 298
2012 399
2013 406
2014 499
2015 535
2016 605
2017 639
2018 765
2019 826
2020 1031
2021 1149
2022 1320
2023 1384
2024 1548
2025 1378

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,033 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. Among authors: hu mi. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
Hu H, Zhang J, Li Y, Wang X, Wang Z, Wang H, Kang L, Liu P, Lan P, Wu X, Zhen Y, Pei H, Huang Z, Zhang H, Chen W, Zeng Y, Lai J, Wei H, Huang X, Chen J, Chen J, Tao K, Xu Q, Peng X, Liang J, Cai G, Ding K, Ding Z, Hu M, Zhang W, Tang B, Hong C, Cao J, Huang Z, Cao W, Li F, Wang X, Wang C, Huang Y, Zhao Y, Cai Y, Ling J, Xie X, Wu Z, Shi L, Ling L, Liu H, Wang J, Huang M, Deng Y; OPTICAL study group. Hu H, et al. Among authors: hu m. J Clin Oncol. 2024 Sep 1;42(25):2978-2988. doi: 10.1200/JCO.23.01889. Epub 2024 Apr 2. J Clin Oncol. 2024. PMID: 38564700 Clinical Trial.
Vedolizumab: Beyond Inflammatory Bowel Disease.
Li Y, Hu M, Chen Y, Yang XY, Wang Q, Ding J, Hu Y. Li Y, et al. Among authors: hu m. Med Princ Pract. 2025 Jun 19:1-13. doi: 10.1159/000547015. Online ahead of print. Med Princ Pract. 2025. PMID: 40545809 Free PMC article. Review.
Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype.
Hu M, Zhu X, Huang X, Hua L, Lin X, Zhang H, Hu Y, Tong T, Li L, Xuan B, Zhao Y, Zhou Y, Ding J, Ma Y, Jiang Y, Ning L, Zhang Y, Wang Z, Fang JY, Zhang Y, Xiao X, Hong J, Chen H, Li J, Chen H. Hu M, et al. Cell Rep. 2025 May 27;44(5):115589. doi: 10.1016/j.celrep.2025.115589. Epub 2025 Apr 20. Cell Rep. 2025. PMID: 40257861 Free article.
Epibulbar osseous choristoma.
Zhong S, Fu J, Hu M, Zhang X, Cheng P. Zhong S, et al. Among authors: hu m. BMC Ophthalmol. 2025 Apr 11;25(1):199. doi: 10.1186/s12886-025-04024-9. BMC Ophthalmol. 2025. PMID: 40217468 Free PMC article.
Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer's disease.
Lin G, Chancellor SE, Kwon T, Woodbury ME, Doering A, Abdourahman A, Bennett RE, Liao F, Pastika T, Tamm J, Romanul N, Yanamandra K, Hu M, Zhao K, Frosch MP, Grinberg Y, Li H, Das S, Dellovade T, Karran EH, Talanian RV, Biber K, Serrano-Pozo A, Ried JS, Langlois X, Hyman BT. Lin G, et al. Among authors: hu m. Cell Rep. 2025 Jun 24;44(6):115758. doi: 10.1016/j.celrep.2025.115758. Epub 2025 May 29. Cell Rep. 2025. PMID: 40448997 Free PMC article.
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.
Orrú CD, Vaughan DP, Vijiaratnam N, Real R, Martinez-Carrasco A, Fumi R, Jensen MT, Hodgson M, Girges C, Gil-Martinez AL, Stafford EJ, Wu L, Lerche S, Wurster I, Groveman BR, Hughson AG, Ansorge O, Quaegebeur A, Allinson KSJ, Warner TT, Jaunmuktane Z, Misbahuddin A, Leigh PN, Ghosh BCP, Bhatia KP, Church A, Kobylecki C, Hu MTM, Rowe JB, Parchi P, Brockmann K, Foltynie T, Morris HR, Caughey B, Jabbari E. Orrú CD, et al. Among authors: hu mtm. Lancet Neurol. 2025 Jul;24(7):580-590. doi: 10.1016/S1474-4422(25)00157-7. Lancet Neurol. 2025. PMID: 40541208 Free article.
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H, Xia Y, Wang W, Xu C, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lyu T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lyu D, Yu Z, Li X, Tang C, Zhou C, Mei Q, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Pang F, Hu M, Wang K, Wu F, Xu B, Xu L, Wang L, Zhu Y, Li J, Xie Y, Lin X, Cai J, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lyu D, Jiao X, Shi L, Lan G, Yang S, Shang Y, Wang Y, Li B, Jin G, Zheng K, Ma J, Li W, Zhang Z, Li Z, Li Y, Liu Z, Ma X, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhu X, Shen Y, Wang K, Ren X, Zhang Y, Ma S, Zhang J, Song Y, Fang W, Lu Y. Feng H, et al. Among authors: hu m. Cancer Biol Med. 2025 Apr 8;22(3):237-65. doi: 10.20892/j.issn.2095-3941.2024.0503. Cancer Biol Med. 2025. PMID: 40200811 Free PMC article.
13,033 results
You have reached the last available page of results. Please see the User Guide for more information.